CRISPR Therapeutics: capital for the next programs
CRISPR Therapeutics reported $2.3644B of cash, equivalents and marketable securities at June 30, including convertible-note proceeds. That cash figure is not net cash after debt.
CRISPR Therapeutics / CRSPPublic biotechcash-positionDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- $2B is a proposed hurdle based on a historical balance, not guidance or a runway guarantee.
Primary evidence
Reporting date unconfirmed — research candidate
CRISPR Therapeutics Q2 2026 financial resultsPublished 2026-08-03
Potential outcome market
Will CRISPR Therapeutics hold more than $2 billion of cash, equivalents and marketable securities at December 31, 2026?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.